ライフサイエンスコーパス: Cas9

1 :GU-US reporter transgene targeted by CRISPR/Cas9.

2 pecific regions of the DMD gene using CRISPR/Cas9.

3 and expands the temperature range of CRISPR-Cas9.

4 cture of engineered chromosomes generated by Cas9.

5 g genome-wide off-target mutations of CRISPR-Cas9.

6 the genome engineering activities of CRISPR-Cas9.

7 ique for precise genome editing using CRISPR-Cas9.

8 erful multiplex targeting capacity of CRISPR/Cas9.

9 eats (CRISPR)-associated protein-9 nuclease (Cas9), a method called acoustic-transfection.

10 talytically defective Streptococcus pyogenes Cas9, a cytidine deaminase, and an inhibitor of base exc

11 mic VEGFR2 locus using rAAV1-mediated CRISPR/Cas9 abrogates angiogenesis in the mouse models of oxyge

12 A deeper understanding of Cas9 activation and its cleavage mechanism can enable fu

13 ethod that allows temporal control of CRISPR/Cas9 activity based on conditional Cas9 destabilization.

14 one targeted mutations as a result of CRISPR/Cas9 activity.

15 iently in vitro; other Cas proteins (such as Cas9 and Csn2) have accessory roles in the biogenesis ph

16 UN1(-/-) and SUN2(-/-) cells by using CRISPR/Cas9 and found that the loss of SUN1 had no effect on HI

17 gle-base editing in zebrafish using modified Cas9 and its VQR variant with an altered PAM specificity

18 t al.) identify viral proteins that suppress Cas9 and may function like molecular sheaths for the Cas

19 tion or introduction of mutations via CRISPR/Cas9 and that this iPSC-based approach can be used to un

20 ependent manipulation of alleles targeted by Cas9 and traditional recombinase with single-cell specif

21 The system relies on recruitment of Cas9 and transcriptional activation complexes to target

22 CRISPR/Cas9 is a combined protein (Cas9) and an engineered single guide RNA (sgRNA) genome

23 ed to provide an efficacious and safe CRISPR/Cas9 antimicrobial, broadly applicable to Staphylococcus

24 While CRISPR/Cas9 appears to work universally, the efficiency of targ

25 ich expands the temperature range for CRISPR-Cas9 applications.

26 med murine and human cells, we used a CRISPR/Cas9 approach.

27 nd PDE4B genes, respectively, using a CRISPR-Cas9 approach.

28 The key components of CRISPR/Cas9 are guide RNAs (gRNAs) which determine specific seq

29 Programmable nucleases, such as Cas9, are used for precise genome editing by homology-de

30 required to expand the versatility of CRISPR/Cas9 as a robust tool to study novel cardiac gene functi

31 Here, by systematic CRISPR/Cas9-assisted deletions of chromatin accessible regions

32 Here, we developed a CRISPR-Cas9-based 'gene drive array' platform to facilitate eff

33 Cas9, providing an efficient off switch for Cas9-based applications.

34 indicate that the effect of postnatal CRISPR/Cas9-based cardiac gene editing using adeno-associated v

35 To evaluate the feasibility of CRISPR/Cas9-based cardiac genome editing in vivo in postnatal m

36 the V247fs mutation was corrected by CRISPR/Cas9-based genome editing (V247fs-MT-correction).

37 CRISPR/Cas9-based genome editing can easily generate knockout m

38 CRISPR/Cas9-based genome editing offers the possibility to knoc

39 mechanism can enable further optimization of Cas9-based genome-editing specificity and efficiency.

40 es and allows for generation of clean CRISPR/Cas9-based KOs.

41 A CRISPR/Cas9-based screen of PAX5 and IKZF1 transcriptional targ

42 tchpad can be irreversibly altered by CRISPR/Cas9-based targeted mutagenesis, and later read out in s

43 preimplantation embryos with precise CRISPR-Cas9-based targeting accuracy and high homology-directed

44 g off-target activity for the development of Cas9-based therapies against genetic diseases.

45 CRISPR-Cas9 can be applied to correct disease-causing gene muta

46 These data demonstrate that CRISPR-Cas9 can be used to generate multiple subtypes of soft t

47 nterdependent conformational dynamics of the Cas9 catalytic domains (HNH and RuvC), responsible for c

48 utations in the genomic context using CRISPR/Cas9, changed the splicing pattern.

49 ns, we identify a strong correlation between Cas9 cleavage efficiency and the stability of the DNA-RN

50 on gene, transformer-2 (tra-2), using CRISPR/Cas9 (clustered regularly interspaced palindromic repeat

51 The CRISPR/Cas9 complex, a bacterial immune response system, has be

52 To find these inhibitors, we searched cas9-containing bacterial genomes for the co-existence o

53 e synthetic elements to a nuclease-deficient Cas9 (dCas9) in vitro and subsequently deliver the dCas9

54 transcription using a catalytically inactive Cas9 (dCas9).

55 In contrast, Cas9/dCas9-PB chimeras did not result in gene targeting.

56 adeno-associated virus (AAV)-mediated CRISPR/Cas9 delivery to postmitotic photoreceptors is used to t

57 Furthermore, the spectrum of CRISPR/Cas9-derived mutations provides important insights into

58 of CRISPR/Cas9 activity based on conditional Cas9 destabilization.

59 rly Interspaced Palindromic Repeats (CRISPR)/Cas9 did not abolish the inhibitory effects of AICAR on

60 The introduction of Cas9-directed genome editing has expanded adoption of th

61 Further, Cas9-directed tethering of mutant LDB1 to the beta-globi

62 airing between the guide RNA and target DNA, Cas9-DNA interactions, and associated conformational cha

63 Our results highlight the role of Cas9 during CRISPR immunization and provide a useful too

64 conformational dynamics of the endonuclease Cas9 during its activation toward catalysis.

65 The gene editing potential of CRISPR/Cas9 encapsulated by ZIF-8 (CC-ZIFs) is further verified

66 the first demonstration of a non-RNA-guided Cas9 endonuclease and first step towards eliminating the

67 The RNA-guided Cas9 endonuclease can be introduced into cells as a puri

68 d others demonstrated that expression of the Cas9 endonuclease induces a gene-independent response th

69 RNA-guided CRISPR-Cas9 endonucleases are widely used for genome engineerin

70 f the CRISPR-Cas9 systems and may facilitate Cas9 engineering.

71 ombinatorial screening, we employ orthogonal Cas9 enzymes from Staphylococcus aureus and Streptococcu

72 ndency map, we performed genome-scale CRISPR-Cas9 essentiality screens across 342 cancer cell lines a

73 estimate gene-dependency levels from CRISPR-Cas9 essentiality screens while accounting for the copy

74 yte-specific Cas9 mice and demonstrated that Cas9 expression does not affect cardiac function or gene

75 Muscle-restricted Cas9 expression enables direct editing of the mutation,

76 h an integrated fluorescent HIV reporter and Cas9 expression gene were generated.

77 of short guide RNA exposure or the level of Cas9 expression.

78 nd less deleterious alternative to wild-type Cas9 for gene-knockout studies.

79 Adaptation of CRISPR-Cas9 for genome-editing applications has revolutionized

80 Recently, the RNA-guided endonuclease Cas9 from the microbial CRISPR (clustered regularly inte

81 ic mechanism should enable control of CRISPR-Cas9 functionality.

82 Loss of CXCR7 expression by CRISPR-Cas9 gene editing resulted in a halt of cell proliferati

83 CRISPR-Cas9 gene editing revealed that both BTK and B lymphocyt

84 Here the authors employ CRISPR/Cas9 gene editing technology to silence VEGFR2, a major

85 Here we apply CRISPR-Cas9 gene editing to tag a cytoskeletal protein (alpha-t

86 CRISPR/Cas9 gene editing was used to knock out pig conceptus IL

87 Here we combine CRISPR/Cas9 gene editing with an innovative high-throughput gen

88 tions, including gene overexpression, CRISPR/Cas9 gene editing, inducible technologies, optogenetic o

89 consequence of mutations generated by CRISPR/Cas9 gene-editing technology, and alleles designed to be

90 omic Repeats/CRISPR-associated gene9 (CRISPR/Cas9) gene editing technology.

91 Here we implement CRISPR-Cas9 genome editing and transposon-mediated somatic gene

92 CRISPR/Cas9 genome editing generated predicted null mutations i

93 We utilized CRISPR/Cas9 genome editing in human induced pluripotent stem (i

94 Gang et al. report CRISPR/Cas9 genome editing in parasites of the genus Strongyloi

95 Using CRISPR-Cas9 genome editing of bptf in zebrafish to induce a los

96 Here, we demonstrate that CRISPR/Cas9 genome editing of promoters generates diverse cis-r

97 ology and underscore the potential of CRISPR/Cas9 genome editing to advance immunotherapies.

98 Here we applied CRISPR-Cas9 genome editing to disrupt the endogenous human MRP

99 Towards this end, we used CRISPR-Cas9 genome editing to make a single allele knock-in of

100 Here we used CRISPR/Cas9 genome editing to separate catalytic activity-depen

101 Here, we employ diverse CRISPR/Cas9 genome editing tools to generate a series of target

102 :Deltap35KI isogenic iPSC lines using CRISPR/Cas9 genome editing.

103 We used CRISPR/Cas9 genome engineering of Drosophila legless (lgs) and

104 We used CRISPR/Cas9 genome engineering of primary adult and umbilical c

105 The CRISPR-Cas9 genome-editing system is a part of the adaptive imm

106 he safe and efficient delivery of the CRISPR-Cas9 genome-editing system to target cells in human body

107 CRISPR/Cas9 genomics revealed that super-enhancer constituents

108 knockout from MCF7 and A549 cells via Crispr/Cas9 greatly promotes cell viability, colony formation,

109 ed by delivering a CRISPR plasmid expressing Cas9/gRNA and a single-stranded oligodeoxynucleotide HDR

110 cationic lipid-mediated in vivo delivery of Cas9-guide RNA complexes can ameliorate hearing loss in

111 Injection of Cas9-guide RNA-lipid complexes targeting the Tmc1(Bth) a

112 CRISPR-Cas9 has become a facile genome editing technology, yet

113 Although CRISPR/Cas9 has been extensively used to manipulate the germlin

114 Recently, the RNA-guidable feature of CRISPR-Cas9 has been utilized for imaging of chromatin within l

115 we report that mutagenizing MELK with CRISPR/Cas9 has no effect on the fitness of basal breast cancer

116 However, no transgenic lines expressing Cas9 have been developed for the major mosquito disease

117 A crystal structure of an AcrIIC1-Cas9 HNH domain complex shows how AcrIIC1 traps Cas9 in

118 le is known about the catalytic state of the Cas9 HNH nuclease domain, and identifying how the divale

119 CRISPR/Cas9 holds immense potential to treat a range of genetic

120 The bacterial CRISPR-Cas9 immune system has been harnessed as a powerful and

121 9 HNH domain complex shows how AcrIIC1 traps Cas9 in a DNA-bound but catalytically inactive state.

122 GATA4 was interrupted by CRISPR-Cas9 in induced pluripotent stem cells from healthy dono

123 omic repeats (CRISPR)-enzymatically inactive Cas9 in MVM-infected cells increased both cyclin B1 prot

124 PR-Cas systems, including the first reported Cas9 in the archaeal domain of life, to our knowledge.

125 e, transgenic Ae. aegypti strains expressing Cas9 in the germline, resulting in dramatic improvements

126 dominant disease to assess the use of CRISPR/Cas9 in two allele-specific systems, comparing cleavage

127 s that have been developed to deliver CRISPR-Cas9 in vitro and in vivo for various therapeutic purpos

128 ed endonuclease CRISPR-associated protein 9 (Cas9), in particular, has attracted attention for its pr

129 cells in which endogenous Piezo1 was CRISPR/Cas9 inactivated.

130 CRISPR/Cas9 induced high rates (88-100%) of mutagenesis in the

131 -mediated gene disruption strategies rely on Cas9-induced DNA double-strand breaks (DSBs).

132 High proportion (14.2-21.4%) CRISPR/Cas9-induced specific truncation events, either from GhM

133 he discovery of four unique type II-A CRISPR-Cas9 inhibitor proteins encoded by Listeria monocytogene

134 CRISPR/Cas9 is a combined protein (Cas9) and an engineered sing

135 CRISPR-Cas9 is a genome editing technology with major impact in

136 Our findings suggest that CRISPR/Cas9 is a powerful gene editing tool that can uncover no

137 CRISPR/Cas9 is a promising tool for genome-editing DNA in cells

138 etic editing tool, where an inactive form of Cas9 is fused to DNA methyltransferase effectors.

139 A major concern for the use of CRISPR/Cas9 is its tendency to cleave DNA non-specifically at "

140 ver, the practical therapeutic use of CRISPR/Cas9 is still questionable due to current shortcomings i

141 cles that will need to be overcome if CRISPR-Cas9 is to be used in the practice of cardiovascular med

142 Pooled CRISPR-Cas9 knock out screens provide a valuable addition to th

143 ng chromatin immunoprecipitation with CRISPR/Cas9 knockin of GFP fusion, we uncovered the global targ

144 generated and characterized inducible CRISPR/Cas9 knockout human cell lines targeting 209 genes invol

145 Functionally, CRISPR/Cas9 knockout of CD63 resulted in a reduction of LMP1-in

146 mmadelta TCR used in conjunction with CRISPR/Cas9 knockout of the endogenous alphabeta TCR resulted i

147 CRISPR/CAS9 knockout of YAP in hESCs enables Activin to induce

148 Confirmation that S. pyogenes Cas9 lacks the specificity to discriminate between allel

149 Deletion of this locus via CRISPR-Cas9 leads to deregulation of the genes predicted to int

150 o this issue, we design and analyse a CRISPR-Cas9 library with 10 variable-length guides per gene and

151 inding specificity was validated by a CRISPR/Cas9 mediated ZnT8 knock-out.

152 epeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-mediated editing in 22 steps; synV strains exhibit

153 nterspaced short palindromic repeats (CRISPR-Cas9)-mediated gene editing.

154 Most importantly, CRISPR/Cas9-mediated ablation of the entire Id (Id1-4) family i

155 enome, respectively, was assembled to direct Cas9-mediated allotetraploid cotton genome editing.

156 of the different types of indels obtained by Cas9-mediated cleavage of the GFP gene, guided by three

157 Moreover, CRISPR-Cas9-mediated deletion of candidate enhancers/SEs, targe

158 CRISPR/Cas9-mediated deletion of fibroblast growth factor recep

159 CRISPR/Cas9-mediated deletion or silencing of MANTIS with small

160 rrogate the molecular consequences of CRISPR/Cas9-mediated deletions at 17 sites in four loci of the

161 Through CRISPR/Cas9-mediated deletions, we demonstrate a physiological

162 unprecedented exploration of the kinetics of Cas9-mediated DNA cleavage and repair.

163 gene-independent antiproliferative effect of Cas9-mediated DNA cleavage confounds such measurement of

164 ersatility of HUH-tags as fusion partners in Cas9-mediated gene editing and the construction of doubl

165 We used CRISPR/Cas9-mediated gene editing of the Ern1 locus to study th

166 Here we used CrispR-Cas9-mediated gene editing to delete the gene encoding f

167 With CRISPR/Cas9-mediated gene editing to stably knock out and recov

168 hways was confirmed in human cells by CRISPR/Cas9-mediated gene inactivation.

169 The development of CRISPR/Cas9-mediated gene knockout in two ant species opens a n

170 onal transport defects are rescued by CRISPR/Cas9-mediated genetic correction of the FUS mutation in

171 n, inhibition of mTORC by torin 1, or CRISPR/Cas9-mediated genetic knock-out of tuberous sclerosis co

172 Hence, an initial CRISPR/Cas9-mediated genetic modification approach has identifi

173 Although Cas9-mediated genome editing has proven to be a powerful

174 We conclude that CRISPR-Cas9-mediated genome editing is a powerful method for in

175 Here we use CRISPR-Cas9-mediated genome editing to investigate the function

176 , Methanocella paludicola, allowed efficient Cas9-mediated genome editing without the need for a repa

177 ularly interspaced short palindromic repeats/Cas9-mediated genomic modification to investigate B-cell

178 Here, we demonstrate that a CRISPR/Cas9-mediated knockout (KO) of a DnaJ protein, DNAJB6, i

179 ways in primary human CD4(+) T cells through Cas9-mediated knockout and antibody blockade.

180 Myoblast clones with CRISPR/Cas9-mediated knockout of C3G failed to show repression

181 Crispr/Cas9-mediated knockout of caspase b, which acts by prote

182 , PB permitted highly efficient isolation of Cas9-mediated knockout of HPRT, with zero transposon int

183 Using CRISPR-Cas9-mediated knockouts of specific cellular genes, we d

184 Our data suggest that CRISPR/Cas9-mediated NRL disruption in rods may be a promising

185 Furthermore, we show that CRISPR/Cas9-mediated PTEN depletion rendered PTEN wild-type Hec

186 nsitive to MAP kinase inhibition, and CRISPR-Cas9-mediated replacement of WT KRAS with a mutant allel

187 mechanistic and structural understanding of Cas9-mediated RNA-guided DNA targeting and cleavage.

188 r regulating ALAS2 expression through CRISPR/Cas9-mediated site-specific deletion.

189 yst complementation platform based on CRISPR-Cas9-mediated zygote genome editing and show enrichment

190 Cas9-mediated, high-throughput, saturating in situ mutag

191 finger transcriptional repressors and CRISPR-Cas9 methods aiming to reduce transcription by targeting

192 HODS AND We generated cardiomyocyte-specific Cas9 mice and demonstrated that Cas9 expression does not

193 human cancers into the brains of conditional-Cas9 mice resulted in tumors that recapitulate human gli

194 is in pig embryos via zygotic co-delivery of Cas9 mRNA and dual sgRNAs targeting the PDX1 gene, which

195 nd genetic deletion of myomixer using CRISPR/Cas9 mutagenesis abolishes myoblast fusion in vivo.

196 e TargeTron insertion, we developed a CRISPR-Cas9 mutagenesis system for C. difficile.

197 from transposon integration, and enrich for Cas9-mutated cells.

198 The Cas9 nuclease has been adapted to target epigenomic modi

199 rformed random mutagenesis of the RNA-guided Cas9 nuclease to look for variants that provide enhanced

200 effects is important for translating CRISPR-Cas9 nucleases into human therapeutics.

201 tagging of PALM fluorophores through CRISPR-Cas9 offers an excellent opportunity for generating stab

202 5 in FLT3-ITD(+) AML cell lines using CRISPR/Cas9, or primary FLT3-ITD(+) AML samples using locked nu

203 diRNAs were not detected from CRISPR/Cas9- or TALEN-induced DSBs within the examined endogeno

204 Here, we used CRISPR/Cas9- or TALEN-triggered DSBs to characterize diRNAs in

205 terspaced short palindromic repeats (CRISPR)-Cas9 platform for in situ high-content functional analys

206 n concert with a mitochondria-adapted CRISPR/Cas9 platform, could prompt a revolution in mitochondria

207 loped a biochemical method (SITE-Seq), using Cas9 programmed with single-guide RNAs (sgRNAs), to iden

208 Here, we utilize nuclease-deactivated Cas9 protein fused to repetitive peptide epitopes (SunTa

209 The nuclease-deactivated variant of CRISPR-Cas9 proteins (dCas9) fused to heterologous transactivat

210 location of specific sites on DNA by CRISPR Cas9 proteins is governed by binding first to protospace

211 d anti-CRISPR proteins (Acrs) can inactivate Cas9, providing an efficient off switch for Cas9-based a

212 n be generated by direct injection of CRISPR/Cas9 reagents into mouse zygotes.

213 We find that a non-catalytic domain within Cas9, REC3, recognizes target complementarity and govern

214 In general, in vivo germline expression of Cas9 results in substantially higher activity than embry

215 the adult mouse brain following injection of Cas9 ribonucleoprotein (RNP) complexes in the hippocampu

216 An in vitro CRISPR/Cas9 RNA-directed nickase system directs the specific la

217 The CRISPR-Cas9 RNA-guided endonuclease system allows precise and e

218 terspaced, short palindromic repeats and the Cas9 RNA-guided nuclease (CRISPR/Cas9) system provides a

219 structures provided insights into a minimal Cas9 scaffold and revealed the remarkable mechanistic di

220 may function like molecular sheaths for the Cas9 scalpel.

221 Here, we deployed genome-scale CRISPR-Cas9 screening of MYCN-amplified neuroblastoma and found

222 a (AML) human cell lines and a custom CRISPR/Cas9 screening platform, we identify the H3K9 methyltran

223 Here we use CRISPR-Cas9 screening strategies in two distinct human cell lin

224 employs genome-wide loss-of-function CRISPR/Cas9 screening to identify three novel factors for HIV-1

225 Cells edited with the same Cas9-sgRNA complexes are then assayed for mutations at e

226 The toolkit includes 23 Cas9-sgRNA plasmids, 37 promoters of various strengths a

227 n of p205 in B16 melanoma cells using CRISPR/Cas9 showed a similar loss of Asc expression.

228 Here we used CRISPR/Cas9 somatic mutagenesis to test a patterning role for W

229 These natural Cas9-specific "anti-CRISPRs" present tools that can be u

230 genome engineering, but our understanding of Cas9 specificity remains incomplete.

231 d to 45 degrees C for Streptococcus pyogenes Cas9 (SpyCas9), which expands the temperature range for

232 mutagenic efficiency and specificity of the Cas9 strains we engineered, they can be used for high-th

233 Despite recent advances in understanding Cas9 structures and its functional mechanism, little is

234 We show that this homing CRISPR-Cas9 system acts as an expressed genetic barcode that di

235 cus aureus cells harbouring a type II CRISPR-Cas9 system after infection with the staphylococcal bact

236 nterspaced short palindromic repeat (CRISPR)-Cas9 system and measured the quantities of binding of th

237 oof of principle experiments with the CRISPR-Cas9 system as a drive mechanism.

238 luding miRNAs, can be targeted by the CRISPR/Cas9 system despite their lacking an open reading frame

239 et mutations after microinjecting the CRISPR/Cas9 system in metaphase II (MII) oocytes and zygote sta

240 The CRISPR/Cas9 system is a powerful tool for studying gene functio

241 netic disruption of miR-277 using the CRISPR-Cas9 system led to failures in both lipid storage and ov

242 We used the double-nicking CRISPR/Cas9 system to conduct site-specific mutagenesis of SNCA

243 larly interspaced short palindromic repeats)/Cas9 system, first identified in bacteria and archaea as

244 n development of applications for the CRISPR-Cas9 system, from efficient genome editing, to high-thro

245 romosomal loci in live cells with the CRISPR-Cas9 system, then barcodes those loci by DNA sequential

246 nt strategies to edit genes using the CRISPR-Cas9 system.

247 /SCID/IL2rg(-/-) (NSI) mice using the CRISPR/Cas9 system.

248 optimize knockout efficiency with the CRISPR/Cas9 system.

249 knockout HepG2 cells generated by the CRISPR/Cas9 system.

250 repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system is emerging as a robust biotechnology for t

251 ats and the Cas9 RNA-guided nuclease (CRISPR/Cas9) system provides a new opportunity to create progra

252 our mechanistic understanding of the CRISPR-Cas9 systems and may facilitate Cas9 engineering.

253 n was further demonstrated to deliver CRISPR-Cas9 systems to successfully modify and reprogram the ge

254 be achieved by combining the TAEL and CRISPR/Cas9 systems.

255 markable mechanistic diversity of the CRISPR-Cas9 systems.

256 tools beyond the well-characterized Type II Cas9 systems.

257 CRISPR/Cas9-targeted (Gatm(c/c) ) mice displayed a normal perip

258 STR-Seq employs in vitro CRISPR-Cas9-targeted fragmentation to produce specific DNA mole

259 hows allelic regulatory activity, and CRISPR/Cas9 targeting of human chondrocytes demonstrates that t

260 led sheep by oocyte microinjection of CRISPR/Cas9 targeting PDX1, a critical gene for pancreas develo

261 The development of CRISPR/Cas9 technologies has dramatically increased the accessi

262 rrent knowledge of genomic editing by CRISPR/Cas9 technology as a feasible strategy for globally inte

263 The availability of CRISPR/Cas9 technology has enabled the rapid establishment of g

264 es the unprecedented opportunity that CRISPR/Cas9 technology offers for investigating and manipulatin

265 We used CRISPR-Cas9 technology to delete key DNA repair genes in human

266 Here, we deploy CRISPR/Cas9 technology to demonstrate a variety of sophisticate

267 Using CRISPR/Cas9 technology to perturb transcription factors, we dem

268 nterspaced short palindromic repeat (CRISPR)-Cas9 technology, gene-specific small interfering RNAs, a

269 However, using CRISPR/Cas9 technology, we have shown that ACLY is not essentia

270 dery mildew fungal pathogen using the CRISPR/Cas9 technology.

271 epeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology is a powerful tool to manipulate the ge

272 epeats (CRISPR)/CRISPR-associated protein-9 (Cas9) technology, simultaneously with transduction with

273 Using gene editing technology (CRISPR/Cas9), the SIRT1 gene was removed from cervical cancer c

274 icism are major concerns for applying CRISPR-Cas9 to correct genetic mutations.

275 towards eliminating the ribose dependency of Cas9 to develop a XNA-programmable endonuclease.

276 We demonstrate the use of CRISPR-Cas9 to edit an endogenous insect cell gene and alter pr

277 reduce pathogenesis by targeting deactivated Cas9 to either the DNA or the RNA repeats with therapeut

278 sful implementation of CRISPR often requires Cas9 to elicit efficient target knockout in a population

279 Here we employ CRISPR/Cas9 to facilitate use of the dimerisable Cre-recombinas

280 f concept, Fogarty et al. (2017) used CRISPR/Cas9 to genetically ablate the OCT4 gene in human preimp

281 Using CRISPR/Cas9 to genetically inactivate a TWIST2 orthologue, we s

282 ulation of the X. laevis genome using CRISPR/Cas9 to model the human disorder retinitis pigmentosa, a

283 Here the authors use CRISP/Cas9 to reduce alpha-globin expression in hematopoietic

284 ontrol; and circuits that incorporate CRISPR-Cas9 to regulate endogenous genes.

285 Now, CRISPR-Cas9 tools for site-specific genome editing are needed t

286 We describe novel CRISPR/Cas9 transfection plasmids and approaches for the speedy

287 rize the different lesions arising from each Cas9 variant and the resulting repair pathway engagement

288 This shows that Cas9 variants can be used to expand the utility of this

289 base editors that use natural and engineered Cas9 variants with different protospacer-adjacent motif

290 ious insect U6 promoters to construct CRISPR-Cas9 vectors and assessed their utility for site-specifi

291 In addition, an engineered Cas9-VQR variant with 5'-NGA PAM specificities is used t

292 CRISPR/Cas9 was developed such that targeted genomic lesions co

293 CRISPR/Cas9 was used to delete defined rhomboid enhancers media

294 In this study, CRISPR/Cas9 was utilized to successfully target the channel cat

295 Using CRISPR/Cas9, we generated HID-1 KO rat neuroendocrine cells, an

296 enhanced sgRNAs (e-sgRNA) and mRNA encoding Cas9, we show that a single intravenous injection into m

297 ing demonstrates comparable efficiency to WT Cas9, which indicates the suitability of our approach fo

298 he conformation of a catalytically competent Cas9, which is prone for catalysis and whose experimenta

299 ed to co-express, from the same promoter, DD-Cas9 with any other gene of interest without co-modulati

300 pted for genome-scale screening by combining Cas9 with pooled guide RNA libraries.